A portal to the papers beyond paywalls

Bets are a paywall has stopped you from reading a paper at some point. Maybe that paper would have influenced your clinical practice? Saved a life? That might be a stretch, but there is significant evidence to suggest papers behind paywalls are viewed less and have less social media attention.¹ Not ideal if reporting practice-changing results.
We preached the open-access movement in the last article but there are always two sides to a story. Large publishers will argue that protecting the integrity of science through peer-review comes at a cost. COVID is an interesting case study on this argument.
The scientific community responded overwhelmingly to the urgency of the pandemic. There was a dramatic increase in open access and pre-print publications. This resulted in more data sharing, greater collaboration and open public review all at previously unthinkable speed.²
However, in certain instances this was detrimental, an obvious example being hydroxychloroquine. The idea hit the headlines based on what turned out to be a methodically flawed pre-print.³ The story was out before the scientific community had the chance to review, critique and retract the pre-print. It looks like a similar scenario is currently playing out with Ivermectin.⁴ Would this have happened if the paper went through a publisher’s peer-review? It shouldn’t.
References:
- https://link.springer.com/article/10.1007/s11192-015-1547-0
- https://read.qxmd.com/read/33798194/
- https://read.qxmd.com/read/32450107/
- https://www.medpagetoday.com/special-reports/exclusives/93658
- https://read.qxmd.com/read/33424474/
- https://read.qxmd.com/read/27872121/
LEGGI TUTTO https://qxmd.medium.com/?p=4ad560c2bbb8

